Looks like it's a monoclonal antibody design to decrease inflammation. The target is people with persistent, low levels of inflammation and major depression.

My institution doesn't give access, but my first question would be whether they accounted for treatment for the underlying cause of the inflammation. Persistent inflammation can cause all sorts of issues and I suppose a treatment for relief is good, but why does it exist? Treating the underlying condition seems more prudent unless they don't know the cause.